edoc

Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B

Scherrer, Alexandra U. and Ledergerber, Bruno and von Wyl, Viktor and Böni, Jürg and Yerly, Sabine and Klimkait, Thomas and Bürgisser, Philippe and Rauch, Andri and Hirschel, Bernard and Cavassini, Matthias and Elzi, Luigia and Vernazza, Pietro L. and Bernasconi, Enos and Held, Leonhard and Günthard, Huldrych F. and Swiss HIV Cohort Study, . (2011) Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. Clinical infectious diseases, Vol. 53, H. 11. pp. 1143-1152.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6004823

Downloads: Statistics Overview

Abstract

Background. Antiretroviral compounds have been predominantly studied in human immunodeficiency virus type 1 (HIV-1) subtype B, but only similar to 10% of infections worldwide are caused by this subtype. The analysis of the impact of different HIV subtypes on treatment outcome is important. Methods. The effect of HIV-1 subtype B and non-B on the time to virological failure while taking combination antiretroviral therapy (cART) was analyzed. Other studies that have addressed this question were limited by the strong correlation between subtype and ethnicity. Our analysis was restricted to white patients from the Swiss HIV Cohort Study who started cART between 1996 and 2009. Cox regression models were performed; adjusted for age, sex, transmission category, first cART, baseline CD4 cell counts, and HIV RNA levels; and stratified for previous mono/dual nucleoside reverse-transcriptase inhibitor treatment. Results. Included in our study were 4729 patients infected with subtype B and 539 with non-B subtypes. The most prevalent non-B subtypes were CRF02_AG (23.8%), A (23.4%), C (12.8%), and CRF01_AE (12.6%). The incidence of virological failure was higher in patients with subtype B (4.3 failures/100 person-years; 95% confidence interval [CI], 4.0-4.5]) compared with non-B (1.8 failures/100 person-years; 95% CI, 1.4-2.4). Cox regression models confirmed that patients infected with non-B subtypes had a lower risk of virological failure than those infected with subtype B (univariable hazard ratio [HR], 0.39 [95% CI,.30-. 52; P > .001]; multivariable HR, 0.68 [95% CI,.51-.91; P = .009]). In particular, subtypes A and CRF02_AG revealed improved outcomes (multivariable HR, 0.54 [95% CI,.29-.98] and 0.39 [95% CI,.19-.79], respectively). Conclusions. Improved virological outcomes among patients infected with non-B subtypes invalidate concerns that these individuals are at a disadvantage because drugs have been designed primarily for subtype B infections.
Faculties and Departments:03 Faculty of Medicine > Departement Biomedizin > Division of Medical Microbiology > Molecular Virology (Klimkait)
UniBasel Contributors:Klimkait, Thomas
Item Type:Article, refereed
Article Subtype:Research Article
Bibsysno:Link to catalogue
Publisher:Oxford University Press
ISSN:1058-4838
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:08 May 2015 08:44
Deposited On:06 Dec 2013 09:36

Repository Staff Only: item control page